UA81423C2 - PRODUCT CONTAINING SRI AND AGONIST OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION - Google Patents

PRODUCT CONTAINING SRI AND AGONIST OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION

Info

Publication number
UA81423C2
UA81423C2 UAA200500883A UA2005000883A UA81423C2 UA 81423 C2 UA81423 C2 UA 81423C2 UA A200500883 A UAA200500883 A UA A200500883A UA 2005000883 A UA2005000883 A UA 2005000883A UA 81423 C2 UA81423 C2 UA 81423C2
Authority
UA
Ukraine
Prior art keywords
agonist
treatment
product containing
5ht2a receptor
thermoregulatory dysfunction
Prior art date
Application number
UAA200500883A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA81423C2 publication Critical patent/UA81423C2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA200500883A 2002-08-15 2003-08-14 PRODUCT CONTAINING SRI AND AGONIST OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION UA81423C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40369202P 2002-08-15 2002-08-15
PCT/US2003/025650 WO2004016256A2 (fr) 2002-08-15 2003-08-14 Agonisme du recepteur 5ht2a pour le traitement du dysfonctionnement de la thermoregulation

Publications (1)

Publication Number Publication Date
UA81423C2 true UA81423C2 (en) 2008-01-10

Family

ID=31888268

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200500883A UA81423C2 (en) 2002-08-15 2003-08-14 PRODUCT CONTAINING SRI AND AGONIST OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION

Country Status (18)

Country Link
US (1) US20040063721A1 (fr)
EP (1) EP1534258A2 (fr)
JP (1) JP2006500366A (fr)
KR (1) KR20050040921A (fr)
CN (2) CN101099734A (fr)
AU (1) AU2003256430A1 (fr)
BR (1) BR0313624A (fr)
CA (1) CA2494687A1 (fr)
CO (1) CO5690568A2 (fr)
EC (1) ECSP055599A (fr)
GE (1) GEP20074192B (fr)
IL (1) IL166586A0 (fr)
MX (1) MXPA05001803A (fr)
NO (1) NO20051304L (fr)
RU (2) RU2340333C2 (fr)
UA (1) UA81423C2 (fr)
WO (1) WO2004016256A2 (fr)
ZA (1) ZA200501308B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102004026679A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
DE102005034498A1 (de) * 2005-07-20 2007-01-25 Grünenthal GmbH Orale Kontrazeption mit Trimegeston
WO2007142810A2 (fr) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Procédés d'utilisation de doxépine faiblement dosée pour améliorer le sommeil
WO2007136741A2 (fr) * 2006-05-19 2007-11-29 Somaxon Pharmaceuticals, Inc. N-desméthyldoxépine et procédés pour traiter les troubles du sommeil l'utilisant
US20100179214A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20100179215A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20080058408A1 (en) 2006-05-19 2008-03-06 Rogowski Roberta L Low-dose doxepin for treatment of sleep disorders in elderly patients
WO2007146073A2 (fr) * 2006-06-09 2007-12-21 Wyeth Procédé destiné à renforcer la fonction cognitive
CA2693992C (fr) 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methodes destinees a ameliorer la pharmacocinetique de la doxepine
US20080182890A1 (en) * 2006-10-04 2008-07-31 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
WO2008052139A2 (fr) 2006-10-25 2008-05-02 Somaxon Pharmaceuticals, Inc. Doxepine à dose ultrafaible, et ses procédés d'utilisation pour traiter des troubles du sommeil
WO2008060397A2 (fr) * 2006-11-03 2008-05-22 Noven Therapeutics, Llc Procédé de traitement d'un dysfonctionnement de la thermorégulation
WO2008070795A2 (fr) * 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Polythérapie utilisant de la doxépine à faible dose pour l'amélioration du sommeil
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
CA2721133C (fr) 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Formulations de doxepine a faible dose et procede de preparation et d'utilisation de celle-ci
WO2009137531A2 (fr) * 2008-05-06 2009-11-12 Somaxon Pharmaceuticals, Inc. Compositions et procédés se rapportant à l'action de faibles dosages de doxépine sur les récepteurs h1 et 5-ht2a
EP2510949A4 (fr) 2009-12-11 2013-11-13 Astellas Pharma Inc Agent thérapeutique pour la fibromyalgie
WO2011109367A2 (fr) * 2010-03-02 2011-09-09 Royster Jr George E Procédés et compositions pour traiter ou prévenir les symptômes de changements hormonaux
US20250295611A1 (en) * 2022-04-27 2025-09-25 Tessellate Therapeutics Inc. Methods of treating 5ht2a receptor-mediated conditions
WO2025008804A1 (fr) * 2023-07-06 2025-01-09 M – Path Biopharma Ltd. Polythérapie pour apporter des améliorations aux effets secondaires d'un traitement par inhibiteurs des récepteurs des œstrogènes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904127D0 (sv) * 1989-12-07 1989-12-07 Astra Ab New biocyclic amino-substituted compounds
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
CA2083698C (fr) * 1990-06-01 1997-11-04 Albert A. Carr (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US5131149A (en) * 1991-06-19 1992-07-21 Lynn C. Thompson Folding knife
EP0714663A3 (fr) * 1994-11-28 1997-01-15 Lilly Co Eli Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
SE510305C2 (sv) * 1997-05-30 1999-05-10 Astra Ab Nytt salt
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms

Also Published As

Publication number Publication date
AU2003256430A1 (en) 2004-03-03
BR0313624A (pt) 2005-06-21
WO2004016256A2 (fr) 2004-02-26
MXPA05001803A (es) 2005-08-16
RU2008123243A (ru) 2009-12-27
RU2340333C2 (ru) 2008-12-10
ECSP055599A (es) 2005-07-06
EP1534258A2 (fr) 2005-06-01
ZA200501308B (en) 2009-09-30
GEP20074192B (en) 2007-09-10
US20040063721A1 (en) 2004-04-01
JP2006500366A (ja) 2006-01-05
NO20051304L (no) 2005-05-06
CN101099734A (zh) 2008-01-09
IL166586A0 (en) 2006-01-15
CA2494687A1 (fr) 2004-02-26
CO5690568A2 (es) 2006-10-31
CN1674880A (zh) 2005-09-28
RU2005104815A (ru) 2005-08-27
KR20050040921A (ko) 2005-05-03
WO2004016256A3 (fr) 2004-06-17

Similar Documents

Publication Publication Date Title
UA81423C2 (en) PRODUCT CONTAINING SRI AND AGONIST OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
UA74419C2 (uk) Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату
GEP20074197B (en) 5ht2c receptor modulators
PH12012501640A1 (en) Novel compounds as opioid receptor modulators
TW200504034A (en) Therapeutic agents
TW200531689A (en) Therapeutic agents
TW200505824A (en) Bicyclic amino acids as pharmaceutical agents
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2005107726A3 (fr) Procede pour le traitement de mal de dos
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
IL172582A0 (en) Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
TW200635903A (en) Therapeutic agents
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
SI1545537T1 (sl) Agonisti alfa-7 nikoninskega receptorja in statini v kombinaciji
TW200738238A (en) Combination of a long-acting hypnotic agent and a short-acting hypnotic agent, pharmaceutical composition containing it and its application in therapeutics
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
UA86024C2 (ru) Трициклические дельта-опиоидные модуляторы
TW200633986A (en) Therapeutic agents
AU9543601A (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
TW200509933A (en) Therapeutic agents
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
TW200728300A (en) Therapeutic agents